Tekmira partner starts human trials of ALN-TTR01

Alnylam Pharmaceuticals (NASDAQ:ALNY), one of Tekmira Pharmaceuticals‘ (TSX:TKM) partners, has initiated dosing in a Phase 1 clinical trial of its ALN-TTR01 product candidate in patients with transthyretin-mediated amyloidosis (ATTR), a disease that results in damage to the peripheral nerves and heart. ALN-TTR01 is a RNA-interference therapeutic that uses Tekmira’s lipid nanoparticle delivery technology, SNALP (stable [...]